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• Principal Investigator: J. Randolph Hecht
• IRB Approved: Yes
LESSONS LEARNED
• The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and
placebo group.
• The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients with meta-
static KRASmutant colorectal carcinoma.
ABSTRACT
Background. Simtuzumab, a humanized IgG4 monoclonal anti-
body to lysyl oxidase-like 2 (LOXL2), blocks desmoplastic reac-
tion in colorectal carcinoma (CRC) cells in vitro.
Methods. Patients with metastatic Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutant CRC were randomized to
receive second-line 5-fluorouracil, leucovorin, and irinotecan
(FOLFIRI) with either 200 or 700 mg simtuzumab or placebo
every 2 weeks in cycles of 28 days. Progression-free survival
(PFS), overall survival (OS), objective response rate (ORR), and
safety were assessed.
Results. In total, 249 patients were randomized and treated
with FOLFIRI/simtuzumab 700 mg (n5 84), FOLFIRI/simtuzu-
mab 200 mg (n5 85), and FOLFIRI/placebo (n5 80). After a
median follow-up of 5.1, 3.8, and 5.5 months, respectively,
median PFS for each of the respective treatment groups was 5.5
months (adjusted HR [95% CI], p value versus placebo; 1.32
[0.92, 1.89]; p5 .10), 5.4 months (1.45 [1.01, 2.06]; p5 .04),
and 5.8 months. Median OS was 11.4 months (1.23 [0.80, 1.91];
p5 .25), 10.5 months (1.50 [0.98, 2.30]; p5 .06), and 16.3
months, respectively. ORR was 11.9%, 5.9%, and 10%,
respectively. Simtuzumab was tolerable in metastatic KRAS
mutant CRC patients.
Conclusion. The addition of simtuzumab to FOLFIRI did not
improve clinical outcomes in patients with metastatic KRAS
mutant CRC. The Oncologist 2017;22:243–e23
DISCUSSION
Stroma in the tumor environment is associated with higher
numbers of activated fibroblasts, which contribute to the des-
moplastic reaction. Tumor-associated activated fibroblasts
secrete oncogenic growth factors, produce extracellular matrix
(ECM), and promote epithelial cell transformation. Lysyl
oxidase-like 2 (LOXL2), an extracellular matrix enzyme that
remodels ECM, is thought to contribute to the maintenance of
the pathologic stromal microenvironment in cancer and fibrotic
diseases and to promote tumor angiogenesis and metastatic
progression. LOXL2 is expressed in desmoplastic tumors, includ-
ing CRC, with no expression in the adjacent nonneoplastic
areas. Simtuzumab, a humanized IgG4 monoclonal antibody to
LOXL2, inhibits its enzymatic activity.
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Clinical Trial Results
In preclinical studies with antibody precursors to simtuzumab,
inhibition of LOXL2 expression reduced the number of activated
fibroblasts, decreased ECM deposition, inhibited angiogenesis,
and prevented tumor cell invasion and metastases. In a phase I
study in patients with advanced solid tumors, simtuzumab
reduced the size of several tumors in some patients.
We assessed the additive efficacy of simtuzumab in a mul-
ticenter, randomized, double-blind, placebo-controlled, phase
II study of simtuzumab or placebo in combination with FOLFIRI
as a second-line therapy in patients with metastatic KRAS-
mutant adenocarcinoma of the colon or rectum not amenable
to complete surgical resection, who previously failed fluoro-
pyrimidine and oxaliplatin therapy (ClinicalTrials.gov
#NCT01479465). Eligible patients had metastatic disease; East-
ern Cooperative Oncology Group performance status (ECOG
PS) 2; adequate bone marrow, hepatic, and renal function;
and estimated life expectancy >3 months. Patients were
randomized 1:1:1 to receive intravenous FOLFIRI in combina-
tion with 700 mg simtuzumab, 200 mg simtuzumab, or pla-
cebo every 2 weeks in cycles of 28 days until disease
progression or unacceptable toxicity; randomization was
stratified by ECOG PS 0 versus >0. From December 2011 to
March 2014, 255 patients were enrolled and 249 patients
received at least 1 cycle of study drug, with a median number
of 6 cycles. Overall, 231 (90.6%) patients discontinued study
drug, mainly due to disease progression (185 [72.5%]) and
adverse events (12 [4.7%]). The majority of patients were male
(128/249, 51.4%) and white (212/249, 85.1%), with a mean
(range) age of 60.5 (22.0–85.0) years and a mean 20.3 months
from diagnosis. A sequential stepwise hypothesis and a Hoch-
berg testing procedure were used to compare between the
two simtuzumab dosing groups versus placebo for PFS, OS,
and ORR. The efficacy analyses failed to demonstrate improve-
ment in clinical endpoints upon the addition of simtuzumab to
FOLFIRI chemotherapy (Table 1). Results from additional sensi-
tivity analyses were consistent with the primary analyses. The
safety profile in the patient groups who received FOLFIRI and
simtuzumab did not differ from that in the FOLFIRI and placebo
group. Among seven adverse events that led to death, a case
of febrile neutropenia was deemed related to treatment with
FOLFIRI.
Table 1. The efficacy endpoints (FAS analysis set)
Endpoint
Simtuzumab
700 mg/FOLFIRI
n5 84
Simtuzumab
200 mg/FOLFIRI
n5 85
Placebo/FOLFIRI
n5 80
PFSa
KM estimate, months, median (95% CI) 5.5 (4.0, 7.1) 5.4 (3.4, 5.6) 5.8 (4.9, 9.0)
Adjusted HR versus placebo (95% CI) 1.32 (0.92, 1.89) 1.45 (1.01, 2.06) —
p value versus placebob .1042 .0395 —
OS
KM estimate, months, median (95% CI) 11.4 (9.7, 15.6) 10.5 (9.2, 12.6) 16.3 (12.0, 19.5)
Adjusted HR versus placebo (95% CI) 1.23 (0.80, 1.91) 1.50 (0.98, 2.30) —
p value versus placebob .2451 .0607 —
ORRa
CR1 PR, n (%) 10 (11.9) 5 (5.9) 8 (10.0)
Difference in ORR from placebo
(95% CI), %
2.0 (28.1, 11.9) 24.1 (213.3, 4.6) —
p value versus placeboc .6904 .3311 —
aStratified primary analysis per investigator assessment. The results per Independent Review Committee were similar to those obtained by investi-
gator assessment. bp values based on stratified two-sided log-rank test. cp values based on Cochran–Mantel–Haenszel test adjusted for stratifica-
tion factors. Abbreviations: CI, confidence interval; CR, complete response; FAS, full analysis set (all patients randomized and treated with 1 dose
of study drug); HR, hazard ratio; KM, Kaplan–Meier; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial
response.
TRIAL INFORMATION
Disease Colorectal cancer
Stage of disease/treatment Metastatic/Advanced
Prior therapy First-line oxaliplatin- and fluoropyrimidine-containing regimen
Type of study - 1 Phase II
Type of study - 2 Randomized
ORR Difference in ORR from placebo, stratified (primary) analysis was 2.0% for the
simtuzumab 700 mg arm (p5 .69), and 24.1% for the simtuzumab 200 mg arm
(p5 .33).
PFS The median PFS was 5.5 months, (HR 1.32, 0.92, 1.89; p5 .10) in the 700 mg
simtuzumab arm, 5.4 months (HR 1.45, 1.01, 2.06, p5 .04) in the 200 mg
simtuzumab arm, and 5.8 month in the control arm
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Primary endpoint Progression-free survival
Secondary endpoint Overall response rate
Secondary endpoint Overall survival
Secondary endpoint Safety
Additional details of endpoints or study design
Patients had to have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, defined with all of following criteria:
(a) lesions accurately measured in at least one dimension, (b) longest diameter in the plane of measurement was recorded, and (c) minimum
size of 10 mm if computed tomography slice thickness 5 mm; if thickness was >5 mm, then the minimum size of measurable lesions was
twice the slice thickness. Patients were excluded if they had more than one prior chemotherapy regimen for stage IV/metastatic colorectal
cancer; underwent an experimental medical treatment within 30 days prior to study entry; received an antitumor therapy (chemotherapy,
antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 21 days prior to randomization; or had cerebral
metastases, uncontrolled hypertension, coronary heart disease, liver disease, or uncontrolled infection. Treatments were administered on day
1 and 15 of each 28-day cycle. Simtuzumab or placebo was given by IV infusion over 30 minutes. FOLFIRI consisted of 200 mg/m2 leucovorin
or 400 mg/m2 dl-leucovorin administered as a 2-hour infusion; 180 mg/m2 irinotecan given as a 90-minute infusion in 500 mL dextrose 5%
via a Y-connector; and 400 mg/m2 fluorouracil bolus followed by a 46-hour infusion of 2,400 mg/m2 fluorouracil. Efficacy was analyzed in all
randomized patients who received at least one dose of study drug (full analysis set [FAS]) based on investigator assessment. Safety analysis
set included patients in the FAS population grouped for analyses with treatment assignments designated according to the actual study drug
received. Safety assessments included the incidence of adverse events (AEs), infusion site reactions, and clinically relevant changes in labora-
tory values and vital signs. AEs were coded according to MedDRA version 17.1 and graded per National Cancer Institute Common Toxicity
Criteria (CTCAE version 4.03). Overall response rate (ORR) was assessed by the investigator per RECIST v1.1 as complete response (CR), partial
response (PR), stable disease (SD), or progressive disease (PD). The difference in PFS and OS from placebo was assessed using Kaplan–Meier
methods and the stratified log-rank test, adjusted for the stratification factor ECOG 0 or >0 at randomization. Cochran–Mantel–Haenszel test
was used for calculating difference in ORR from placebo. A sequential stepwise hypothesis and a Hochberg testing procedure were used to
compare between simtuzumab dosing groups versus placebo for PFS, OS, and ORR, per investigator assessment. A number of sensitivity
analyses for PFS, OS, and ORR were also performed to confirm the results of primary analyses. A total of 185 PFS events had to be observed
in this study to detect a hazard ratio of 0.6 with approximately 90% power at a two-sided 0.05 significance level based on Hochberg
procedure to claim that at least one of the simtuzumab treatment groups improved PFS significantly compared with placebo. The
estimated sample size was 255 patients.
Investigator’s analysis Level of activity did not meet planned endpoint.
DRUG INFORMATION CONTROL ARM
Drug 1
Generic/Working name Folinic acid (leucovorin)
Drug type Small molecule
Drug class Antimetabolite
Dose 200 mg/m2
Route IV over 2 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 2
Generic/working name 5-FU
Drug type Small molecule
Drug class Antimetabolite
Dose 2,400 mg/m2 (bolus 400 mg/m2)
Route Continuous intravenous infusion (CIV) over 46 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 3
Generic/working name Irinotecan
Drug type Small molecule
Drug class Inhibitor of topoisomerase I
Dose 180 mg/m2
Route IV over 1.5 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
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DRUG INFORMATION EXPERIMENTAL ARM A: SIMTUZUMAB 200 MG
Drug 1
Generic/working name Simtuzumab (GS-6624)
Company name Gilead Sciences, Inc.
Drug type Antibody
Drug class Inhibitor of lysyl oxidase-like 2 enzyme
Dose 200 mg per flat dose
Route IV
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 2
Generic/working name Leucovorin
Drug type Small molecule
Drug class Antimetabolite
Dose 200 mg/m2
Route IV over 2 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 3
Generic/working name 5-FU
Drug type Small molecule
Drug class Antimetabolite
Dose 2,400 mg/m2 (bolus 400 mg/m2)
Route Continuous intravenous infusion (CIV) over 46 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 4
Generic/working name Irinotecan
Drug type Small molecule
Drug class Inhibitor of topoisomerase I
Dose 180 mg/m2
Route IV over 1.5 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
DRUG INFORMATION EXPERIMENTAL ARM B: SIMTUZUMAB 700 MG
Drug 1
Generic/working name Simtuzumab (GS-6624)
Company name Gilead Sciences, Inc.
Drug type Antibody
Drug class Inhibitor of lysyl oxidase-like 2 enzyme
Dose 700 mg per flat dose
Route IV
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 2
Generic/working name Leucovorin
Drug type Small molecule
Drug class Antimetabolite
Dose 200 mg/m2
Route IV over 2 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
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PATIENT CHARACTERISTICS
Number of patients, male 128
Number of patients, female 121
Stage Advanced, metastatic, stage IV
Age Median (range), years: 700 mg simtuzumab, 61 (22–78); 200 mg simtuzumab, 64
(31–83); placebo, 60.5 (32–85)
Number of prior systemic therapies 1, first-line oxaliplatin- and fluoropyrimidine-containing regimen
Performance status: ECOG 0 — 118
1 — 126
2 — 5
Drug 3
Generic/working name 5-FU
Drug type Small molecule
Drug class Antimetabolite
Dose 2,400 mg/m2 (bolus 400 mg/m2)
Route Continuous intravenous infusion (CIV) over 46 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
Drug 4
Generic/working name Irinotecan
Drug type Small molecule
Drug class Inhibitor of topoisomerase I
Dose 180 mg/m2
Route IV over 1.5 hours
Schedule of administration Day 1 and 15 of each 28-day cycle
PRIMARY ASSESSMENT METHOD
Control Arm:
Number of patients enrolled 84
Number of patients evaluable for toxicity 80
Number of patients evaluated for efficacy 80
Response assessment CR n5 0 (0%)
Response assessment PR n5 8 (10%)
Response assessment SD n5 53 (66%)
Response assessment PD n5 17 (21%)
Response assessment OTHER n5 2 (3%)
(Median) duration assessments PFS 5.8 months, CI: 4.9–9.0
(Median) duration assessments OS 16.3 months, CI: 12.0–19.5
Experimental Arm A: Simtuzumab 200 mg
Number of patients enrolled 86
Number of patients evaluable for toxicity 85
Number of patients evaluated for efficacy 85
Response assessment CR n5 0 (0%)
Response assessment PR n5 5 (6%)
Response assessment SD n5 50 (59%)
Response assessment PD n5 23 (27%)
Response assessment OTHER n5 7 (8%)
Hecht, Benson, Vyushkov et al. e18
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(Median) duration assessments PFS 5.4 months, CI: 3.4–5.6
(Median) duration assessments OS 10.5 months, CI: 9.2–12.6
Experimental Arm B: Simtuzumab 700 mg
Number of patients enrolled 85
Number of patients evaluable for toxicity 84
Number of patients evaluated for efficacy 84
Response assessment CR n5 0 (0%)
Response assessment PR n5 10 (12%)
Response assessment SD n5 49 (58%)
Response assessment PD n5 23 (27%)
Response assessment OTHER n5 2 (2%)
(Median) duration assessments PFS 5.5 months, CI: 4.0–7.1
(Median) duration assessments OS 11.4 months, CI: 9.7–15.6
ADVERSE EVENTS CONTROL ARM
All Dose Levels, All Cycles
Name *NC/NA 1 2 3 4 5 All Grades
Diarrhea 45% 28% 18% 9% 0% 0% 55%
Nausea 54% 21% 21% 4% 0% 0% 46%
Fatigue 57% 21% 15% 6% 0% 0% 43%
Neutropenia 58% 6% 11% 20% 5% 0% 42%
Vomiting 70% 21% 6% 3% 0% 0% 30%
Decreased appetite 74% 16% 9% 1% 0% 0% 26%
Alopecia 74% 20% 6% 0% 0% 0% 26%
Anemia 76% 10% 8% 6% 0% 0% 24%
Abdominal pain 76% 9% 10% 5% 0% 0% 24%
Stomatitis 79% 9% 8% 5% 0% 0% 21%
Constipation 79% 11% 10% 0% 0% 0% 21%
Asthenia 85% 10% 5% 0% 0% 0% 15%
Pyrexia 87% 9% 4% 0% 0% 0% 13%
Mucosal inflammation 87% 4% 8% 1% 0% 0% 13%
Epistaxis 87% 13% 0% 0% 0% 0% 13%
Leukopenia 88% 3% 6% 3% 0% 0% 12%
Cough 88% 11% 1% 0% 0% 0% 12%
Dyspnea 88% 11% 1% 0% 0% 0% 12%
Insomnia 89% 8% 3% 0% 0% 0% 11%
Hypokalemia 90% 5% 1% 4% 0% 0% 10%
*NC/NA No change from baseline/no adverse event
Adverse events that occurred in 10% of patients. n5 80, safety analysis set. Clinical and laboratory adverse events were coded using the Medical Dic-
tionary for Regulatory Activities (MedDRA) version 16.1 and graded using the National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03).
Serious Adverse Events Control Arm
Name Grade Attribution
Febrile neutropenia 4 Probable
Dehydration 2 Probable
Dehydration 3 Probable
Vomiting 2 Probable
Nausea 2 Probable
Nausea 3 Probable
Diarrhea 3 Probable
Abdominal pain 3 Probable
e19 Simtuzumab/FOLFIRI for Colorectal Cancer
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Enteritis 3 Probable
Gastroenteritis 3 Probable
SAEs deemed related to simtuzumab/placebo. As this was a double-blind study, the SAEs considered related to simtuzumab were recorded for
both treatment arms. SAEs related to FOLFIRI were not collected. n5 80, safety analysis set.
ADVERSE EVENTS BOTH EXPERIMENTAL ARMS
All Dose Levels, All Cycles
Name *NC/NA 1 2 3 4 5 All Grades
Neutropenia 51% 4% 15% 20% 10% 0% 49%
Fatigue 52% 22% 20% 6% 0% 0% 48%
Nausea 52% 27% 21% 0% 0% 0% 48%
Diarrhea 54% 29% 11% 6% 0% 0% 46%
Anemia 74% 9% 13% 4% 0% 0% 26%
Vomiting 74% 18% 7% 1% 0% 0% 26%
Alopecia 75% 16% 9% 0% 0% 0% 25%
Abdominal pain 77% 8% 13% 2% 0% 0% 23%
Constipation 77% 15% 8% 0% 0% 0% 23%
Decreased appetite 80% 10% 8% 2% 0% 0% 20%
Leukopenia 86% 4% 5% 6% 1% 0% 16%
Edema, peripheral 85% 10% 4% 1% 0% 0% 15%
Asthenia 85% 5% 8% 2% 0% 0% 15%
Cough 86% 13% 1% 0% 0% 0% 14%
Stomatitis 86% 8% 5% 1% 0% 0% 14%
Mucosal inflammation 87% 7% 5% 1% 0% 0% 13%
Pyrexia 87% 11% 2% 0% 0% 0% 13%
Dizziness 87% 12% 1% 0% 0% 0% 13%
Dyspnea 88% 8% 4% 0% 0% 0% 12%
Thrombocytopenia 88% 11% 1% 0% 0% 0% 12%
Back pain 89% 6% 3% 2% 0% 0% 11%
Hypokalemia 90% 5% 1% 4% 0% 0% 10%
*NC/NA No change from baseline/no adverse event
Adverse events that occurred in 10% of patients. n5 169, safety analysis set. Clinical and laboratory adverse events were coded using the Medical Dic-
tionary for Regulatory Activities (MedDRA) version 16.1 and graded using the National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03).
Serious Adverse Events Experimental Arm
Name Grade Attribution
Sepsis 4 Probable
Urosepsis 4 Probable
Febrile neutropenia 3 Probable
Febrile neutropenia 4 Probable
Thrombocytopenia 4 Probable
Diverticulitis 3 Probable
Lung infection 2 Probable
Lower respiratory tract inflammation 4 Probable
Pneumothorax 4 Probable
Diarrhea 3 Probable
Delirium 4 Probable
Confusional state 4 Probable
SAEs deemed related to simtuzumab. SAEs related to FOLFIRI were not collected. n5 169, safety analysis set.
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Colorectal cancer (CRC) accounts for 9.7% of all incident
cancers worldwide and is the fourth leading cause of cancer
mortality [1]. One of the frequent genetic mutations in CRC is
in the KRAS gene in the chromosomal instability pathway [2].
KRAS mutation-positive patients do not respond to anti-
epidermal growth factor receptor antibody therapy [3] and
have poorer survival than patients with the KRAS wild-type
gene [4]. The currently available therapies for advanced KRAS-
mutated CRC include chemotherapy alone or in combination
with antiangiogenic antibodies such as bevacizumab, afliber-
cept, or ramucirumab [5]. New therapies are urgently needed
for this patient population.
Activated stroma in the tumor environment is associated
with higher numbers of activated fibroblasts, which contribute
to the desmoplastic reaction [6, 7]. Tumor-associated activated
fibroblasts secrete oncogenic growth factors, produce extracel-
lular matrix (ECM), and promote epithelial cell transformation
[7, 8]. Lysyl oxidase-like 2 (LOXL2), an enzyme that remodels
the ECM, contributes to the maintenance of the pathologic
stromal microenvironment in cancer and fibrotic diseases [9]
and promotes tumor angiogenesis [10] and metastatic progres-
sion [11]. LOXL2 is expressed in desmoplastic tumors, including
CRC, with no expression in the adjacent nonneoplastic areas
[8, 12].
Simtuzumab, a humanized IgG4 monoclonal antibody
against LOXL2, inhibits its enzymatic activity [13]. In preclinical
studies with antibody precursors to simtuzumab, inhibition of
LOXL2 expression reduced numbers of activated fibroblasts,
decreased ECM deposition [9], inhibited angiogenesis [14], and
prevented tumor cell invasion and metastases [15]. Of note, in
preclinical models, simtuzumab had better efficacy in KRAS
mutant cell lines (Gilead Sciences, Inc., data on file). In a phase I
study in patients with advanced solid tumors, single agent sim-
tuzumab reduced the size of several tumors in select patients
[16].
In a multicenter, randomized, double-blind, placebo-con-
trolled phase II study, we evaluated the efficacy of simtuzumab
or placebo in combination with FOLFIRI as a second-line ther-
apy in patients with metastatic KRAS-mutant CRC who pro-
gressed following oxaliplatin- and fluoropyrimidine-containing
first-line therapy (ClinicalTrials.gov #NCT01479465).
The key endpoints included progression-free survival
(PFS), overall survival (OS), objective response rate (ORR)
per RECIST v1.1, and safety. Enrolled patients had stage IV
disease; ECOG PS 2; adequate bone marrow, hepatic, and
renal function; and estimated life expectancy >3 months.
Patients were randomized 1:1:1 to receive intravenous
FOLFIRI in combination with simtuzumab or placebo until
disease progression or unacceptable toxicity; randomiza-
tion was stratified by Eastern Cooperative Oncology Group
performance status (ECOG PS) 0 vs >0. Patients were
scheduled for 2 visits per cycle and a computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) scan every 8
weeks.
From December 2011 to March 2014, 255 patients were
randomized, 249 patients received at least one 28-day cycle of
study drug (full analysis set [FAS]), and 233 (94%) patients
received 2 cycles, with a median number of 6 cycles. The
majority of enrolled patients were male (128/249, 51.4%) and
white (212/249, 85.1%), with a mean (range) age of 60.5 (22.0–
85.0) years (Table 2). The mean (SD) time since first diagnosis of
colorectal cancer was 20.3 (20.31) months. In total, 42% of
patients had 3 or more target lesions at baseline. The most
common target lesion sites included liver (73%), lung (45%),
and lymph nodes (16%) (Table 2).
Overall, 231 (90.6%) patients had discontinued study, mainly
due to disease progression (185 [72.5%]) and adverse events (12
[4.7%]). A sequential stepwise hypothesis and a Hochberg test-
ing procedure were used to compare between the two simtuzu-
mab dosing groups versus placebo for PFS, OS, and ORR. A
number of sensitivity analyses were also conducted for PFS, OS,
and ORR to confirm the results of the primary analyses. The
study failed to reach any of the prespecified efficacy endpoints.
Median PFS for FOLFIRI/simtuzumab 700 mg, FOLFIRI/simtuzu-
mab 200 mg, and FOLFIRI/placebo was 5.5 months (adjusted
hazard ratios [HRs] with 95% confidence interval [CIs] for the
stratified primary analysis, p value versus placebo; 1.32 [0.92,
1.89]; p5 .10), 5.4 months (1.45 [1.01, 2.06] p5 .04), and 5.8
months, respectively (Fig. 1), after a median follow-up of 5.1,
3.8, and 5.5 months, respectively. Median OS for the FOLFIRI/
simtuzumab 700 mg, FOLFIRI/simtuzumab 200 mg, and FOLFIRI/
placebo was 11.4 months (adjusted HR, [95% CIs] for the strati-
fied OS primary analysis, p value versus placebo; 1.23 [0.80,
1.91]; p5 .25), 10.5 months (1.50 [0.98, 2.30]; p5 .06), and
16.3 months, respectively (Fig. 2). The adjusted HRs for PFS and
OS for the simtuzumab arms compared with placebo were all
greater than 1. The ORRs in FOLFIRI/simtuzumab 700 mg, FOL-
FIRI/simtuzumab 200 mg, and FOLFIRI/placebo were 11.9%,
5.9%, and 10.0%, respectively. The difference (95% CI) in ORR for
patients treated with 700 mg FOLFIRI plus simtuzumab versus
patients treated with FOLFIRI plus placebo was 2.0% (28.1,
11.9; p5 .69) and 24.1% (213.3, 4.6; p5 .33) for patients
treated with 200 mg FOLFIRI plus simtuzumab compared with
FOLFIRI plus placebo. Results from sensitivity analyses were con-
sistent with the primary analyses.
The safety profile in the patient groups who received FOL-
FIRI combined with simtuzumab was not different from patients
who received FOLFIRI with placebo. The most common adverse
events (AEs) deemed by the investigator to be related to study
treatment were fatigue, diarrhea, nausea and neutropenia. AEs
greater than or equal to grade 3 were reported in 59.5% in the
FOLFIRI/simtuzumab 700 mg group, 67.1% in the FOLFIRI/sim-
tuzumab 200 mg group, and 61.3% in the FOLFIRI/placebo
group. Seven AEs leading to death occurred during this study;
one case of febrile neutropenia was deemed related to FOLFIRI
treatment. None of the deaths on study were considered
related to simtuzumab.
In conclusion, the addition of simtuzumab to FOLFIRI did
not improve PFS, OS, or ORR in patients with metastatic KRAS
mutant CRC.
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Pharmacokinetics/Pharmacodynamics Not Collected
Investigator’s Assessment Level of activity did not meet planned endpoint
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FIGURES AND TABLES
Figure 1. Stratified Kaplan–Meier plot of progression-free survival
by investigator assessment (FAS population).
Abbreviations: CI, confidence interval; FAS, full analysis set (all
patients randomized and treated with1 dose of study drug); HR,
hazard ratio (numbers in brackets are 95% CIs); PFS, progression-
free survival; SIM, simtuzumab.
Figure 2. Stratified Kaplan–Meier plot of overall survival (FAS
population).
Abbreviations: CI, confidence interval; FAS, full analysis set (all
patients randomized and treated with1 dose of study drug); HR,
hazard ratio (numbers in brackets are 95% CIs); OS, overall sur-
vival; SIM, simtuzumab.
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Table 2. Demographic and baseline characteristics (FAS analysis set)
Characteristic
Simtuzumab 700 mg/
FOLFIRI n5 84
Simtuzumab 200 mg/
FOLFIRI n5 85
Placebo/FOLFIRI
n5 80
Mean age in years (range) 60.1 (22.0–78.0) 62.6 (31.0–83.0) 58.8 (32.0–85.0)
ECOG performance status, n (%)
0 35 (41.7) 40 (47.1) 43 (53.8)
1 48 (57.1) 42 (49.4) 36 (45.0)
2 1 (1.2) 3 (3.5) 1 (1.3)
Mean time since first diagnosis of colorectal
cancer in months (SD)
20.7 (24.72) 20.5 (17.53) 19.6 (17.87)
Patients with prior chemoimmunotherapy, n (%) 84 (100) 85 (100) 80 (100)
Patients with prior radiotherapy related to
current disease, n (%)
13 (15.5) 17 (20.0) 16 (20.0)
No. of target lesions at baseline, n (%)
1 12 (14.3) 11 (12.9) 14 (17.5)
2 31 (36.9) 35 (41.2) 39 (48.8)
3 20 (23.8) 18 (21.2) 16 (20.0)
4 12 (14.3) 15 (17.6) 9 (11.3)
5 8 (9.5) 5 (5.9) 2 (2.5)
Lesion site, n (%)
Liver 59 (70.2) 64 (75.3) 58 (72.5)
Lung 42 (50.0) 37 (43.5) 34 (42.5)
Lymph nodes (shortest diameter) 14 (16.7) 15 (17.6) 11 (13.8)
Mean tumor sum of diameter at baseline per
investigator in millimeters (SD)
90.3 (57.38) 87.9 (58.04) 77.2 (52.54)
Mean tumor sum of diameter at baseline per
IRR in millimeters (SD)
89.7 (50.93) 91.1 (50.67) 82.8 (61.45)
Mean tumor marker CEA in lg/L (SD) 264.7 (861.88) 462.8 (1325.24) 320.3 (970.59)
Abbreviations: CEA, carcinoembryonic antigen; FAS, full analysis set (all patients randomized and treated with 1 dose of study drug); IRR, Inde-
pendent Radiology Review; SD, standard deviation.
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